Statera Biopharma Inc. (STAB)
Company Description
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis.
The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers.
It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis.
The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021.
The company is based in Fort Collins, Colorado.
| Country | United States |
| IPO Date | Jul 28, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Dr. Blake Hawley D.V.M., M.B.A. |
Contact Details
Address: 2537 Research Boulevard Fort Collins, Colorado United States | |
| Website | https://www.staterabiopharma.com |
Stock Details
| Ticker Symbol | STAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001318641 |
| CUSIP Number | 857561104 |
| ISIN Number | US8575611046 |
| Employer ID | 20-0077155 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert W. Buckheit Jr., Ph.D. | Chief Technology Officer |
| Christopher Zosh | Executive Vice President of Finance, Interim Principal Financial Officer & Interim Principal Accounting Officer |
| Dr. Blake Hawley D.V.M., M.B.A. | Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 03, 2023 | 25-NSE | Filing |
| Mar 01, 2023 | DEFR14A | Filing |
| Feb 27, 2023 | DEF 14A | Filing |
| Feb 14, 2023 | PRE 14A | Filing |
| Feb 01, 2023 | 8-K | Current Report |
| Feb 01, 2023 | 8-A12G | Filing |
| Jan 20, 2023 | 8-K | Current Report |
| Nov 28, 2022 | DEF 14A | Filing |
| Nov 18, 2022 | PRE 14A | Filing |
| Nov 15, 2022 | 8-K | Current Report |